Download presentation
Presentation is loading. Please wait.
Published byWendy Johns Modified over 6 years ago
1
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole
Stefania Bellone, PhD, Hemendrah R. Shah, MD, Jesse K. McKenney, MD, Pamela J.B. Stone, MD, Alessandro D. Santin, MD American Journal of Obstetrics & Gynecology Volume 199, Issue 3, Pages e7-e10 (September 2008) DOI: /j.ajog Copyright © 2008 Mosby, Inc. Terms and Conditions
2
FIGURE 1 CT scans of recurrent endometrioid adenocarcinoma before the beginning of anastrozole therapy Representative chest (left) and pelvis (right) CT scans before the beginning of anastrozole therapy (upper panel: lung nodule = 1.5 × 1.8 cm; pelvic mass = 4 × 5 cm), after 6 courses of chemotherapy (middle panel: lung nodule = complete response; pelvic mass = 2.4 × 1.8 cm), and after 9 months from the beginning of Arimidex therapy (lower panel: lung nodule = complete response; pelvic mass = 2.0 × 1.4 cm). The arrows indicate metastatic/recurrent target lesions in the lung and pelvis that show regression to therapy. Bellone. Recurrent endometrial carcinoma. Am J Obstet Gynecol 2008. American Journal of Obstetrics & Gynecology , e7-e10DOI: ( /j.ajog ) Copyright © 2008 Mosby, Inc. Terms and Conditions
3
FIGURE 2 Immunohistochemistry staining of recurrent endometrioid adenocarcinoma Hematoxylin-eosin stain of endometrioid adenocarcinoma that was recurrent in the lung (upper panel: original magnification, ×400) with positive ER immunostains (lower panel: original magnification, ×400). Bellone. Recurrent endometrial carcinoma. Am J Obstet Gynecol 2008. American Journal of Obstetrics & Gynecology , e7-e10DOI: ( /j.ajog ) Copyright © 2008 Mosby, Inc. Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.